Targeted radiotherapy with Y-90-DOTA-TYR3-octreotide (Y-90-SMT487; OctreoTher (TM)): A phase I study.

Valkema, R; Jamar, François; Pauwels, Stanislas; Jonard, P.; Bakker, WH; Norenberg, J; Hadley, J; Smith, C; Kvols, L; Krenning, EP

Targeted radiotherapy with Y-90-DOTA-TYR3-octreotide (Y-90-SMT487; OctreoTher (TM)): A phase I study.

Valkema, R

;

Jamar, François

;

Pauwels, Stanislas

;

Jonard, P.

;

Krenning, EP

;et.al.

(2000)

Files

No attached file found for this publication.

Details

Authors

Valkema, R
Author
Jamar, FrançoisUCLouvain
Author
Pauwels, StanislasUCLouvain
Author
Jonard, P.
Author
Krenning, EP
Author

Affiliations

UCLouvainCliniques universitaires Saint-Luc
UCLouvainMD/MINT - Département de médecine interne

Citations

APA
Chicago
FWB

Valkema, R., Jamar, F., Pauwels, S., Jonard, P., Bakker, W., Norenberg, J., Hadley, J., Smith, C., Kvols, L., & Krenning, E. (2000). Targeted radiotherapy with Y-90-DOTA-TYR3-octreotide (Y-90-SMT487; OctreoTher (TM)): A phase I study. The Journal of Nuclear Medicine, 41(5), 111P-111P. (Original work published 2000)